US EditionCampaigners question ethics of puberty-blocker trial in legal letter to Streeting
Campaigners argue the UK NHS Pathways trial risks harm to vulnerable children despite regulatory approval; trial aims to recruit 220 participants to assess puberty blockers' safety and efficacy.
- Campaigners have questioned the ethics of a puberty-blocker trial for children in a legal letter to Wes Streeting, the shadow health secretary.
- Keira Bell, who was given puberty blockers as a teenager and regrets it, said children could be harmed from the trial and their fertility and sexual function affected.
- The Department of Health said the trial will help provide evidence currently lacking, and its approval came after rigorous safety checks with safeguards to protect young people's wellbeing.
23 Articles
23 Articles
Legal Challenge Targets UK National Health Service Puberty Blocker Trial
Campaigners have launched a legal action aimed at suspending a new NHS-funded trial of puberty blockers, claiming the research could harm participating children. The Pathways trial, run by King’s College London, plans to recruit about 226 children aged 10 to 15 over three years. The trial was commissioned following last year’s Cass review, which found gender medicine for minors relied on weak evidence. Participants will either receive puberty bl…
Office smashed three times: UK minister 'uncomfortable' with blocker trial | The latest National and International News
Health Secretary Wes Streeting (Yui Mok/PA) Yui Mok UK Health Secretary Wes Streeting has admitted he is "not comfortable" with a controversial clinical trial testing puberty blockers on children, revealing his constituency office windows have been smashed three times by trans activists since the study launched last month. Speaking on LBC radio on Friday, Streeting said he has received "all sorts of threats" and been "called all the names under …
expert reaction to media reports of campaigners beginning legal action to halt Pathways trial of puberty suppression drugs
Scientists comment on reports that campaigners are beginning legal action to halt the Pathways trial of puberty blockers. Prof Sir Jonathan Montgomery, Professor of Health Care Law, UCL, said: “Campaigners are challenging the decisions of the Medicines and Health Care products Regulatory Agency and the Health Research Authority to authorise a trial that aims to address past failures of evidence-based medicine in the care of young people suffe…
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
